Red light therapy for multiple sclerosis is being studied for the parts of MS that standard treatment does not reach: weakness, spasticity, cellular energy failure, ongoing inflammation, and the progressive damage to nerve-fiber insulation that current medications were not designed to reverse. A placebo-controlled trial measured real strength gains in people with MS. Animal and human-cell studies offer a connected biological explanation for why those gains occurred. The research is real, and it is early. No study has shown that the treatment slows MS progression or reduces relapses. Clinicians call the treatment photobiomodulation, and for MS, the evidence warrants careful examination.
Key Takeaways
- A 2024 meta-analysis of three animal studies found that photobiomodulation reduced MS-model disease severity by 1.44 points on the 0-5 scale used to score mice (95% CI −2.45 to −0.42, p = 0.006), alongside less immune-cell infiltration, less myelin loss, and fewer cell-death markers. (Ahmed, 2024)
- The strongest human trial, a randomized double-blind crossover study in 17 people with MS, found significant gains in muscle strength and in force recovery after fatiguing exercise, both measured with a dynamometer rather than self-reported. The same trial found no improvement in fatigue or endurance. (Rouhani et al., 2024)
- The most defensible role for red light therapy in MS today is as a complementary approach used alongside medical care, under a neurologist's guidance. Human trials remain small, no treatment protocol is standardized, and no trial has measured relapses, MRI lesions, or long-term disability. (Oliveira de Andrade Filho et al., 2024)
What Multiple Sclerosis Does, and Where Treatment Runs Out
Multiple sclerosis is a disease in which the immune system attacks the central nervous system, damaging nerve-fiber insulation and the fibers underneath. Doctors call that insulation myelin; its loss drives most of what MS patients experience, including weakness, pain, fatigue, balance problems, cognitive difficulty, and progressive loss of function. About 2.9 million people worldwide were living with MS as of 2023.
Disease-modifying therapies reduce relapses, limit new inflammatory activity, and delay disability progression. They work. What they were not designed to do is restore function already lost. Rehabilitation and exercise fill part of that gap, and the research community treats it as unfinished business (National MS Society; NINDS).
Photobiomodulation research sits in that space: studying whether red and near-infrared light can influence cellular energy, inflammatory signaling, oxidative stress, and tissue repair (Oliveira de Andrade Filho et al., 2024).
How Red Light Therapy May Affect Multiple Sclerosis
Photobiomodulation uses red and near-infrared light to change biological activity without heating or damaging tissue. The leading explanation centers on light-sensitive processes inside the structures that produce energy in cells. That response can shift energy output, inflammatory signaling, oxidative balance, blood flow, and repair activity. CuraYou's guide to how red light therapy works at the cellular level covers the underlying biology in depth (Wong-Riley et al., 2005).
For MS, the research divides into five pathways. Some have direct human evidence. Others rest on animal or cell studies and should be read as biological rationale, not proven clinical benefit. Each section labels which is which.
Reducing Neuroinflammation and Shifting Immune Signaling
Evidence tier: 2024 meta-analysis of animal studies; human-cell studies; one small uncontrolled human trial; recent animal work
Inflammation in MS drives immune cells into the central nervous system, activates the brain's own immune cells, and sustains damage to myelin and nerve fibers. Across the MS-specific research, reduced inflammatory signaling is the most consistently observed effect of red light therapy.
The pooled animal data represents the strongest quantitative finding in the field. A 2024 meta-analysis found that photobiomodulation reduced disease severity in mice by 1.44 points on a 0-5 scale (95% CI −2.45 to −0.42, p = 0.006), alongside less immune-cell infiltration, less myelin loss, and lower inflammatory activity. (Ahmed, 2024)
Newer animal work tracked immune and nerve activity in living spinal tissue. Daily treatment reduced immune-cell entry into the spinal cord, lowered activation of the brain's resident immune cells, corrected abnormal electrical activity in spinal nerve cells, and improved movement and sensation. Two disclosures: the device combined light with a static magnetic field (so light alone was not isolated), and the device manufacturer was involved in the research (Escarrat et al., 2024).
Human cell research points the same direction. Immune cells drawn from people with MS responded to 670 nm and 830 nm light with shifts toward anti-inflammatory signaling and away from pro-inflammatory signaling. Those experiments do not show that a device produces the same effect inside a patient, but they confirm that immune cells taken from people with MS remain responsive to light (Tolentino, Cho & Lyons, 2022; Tolentino, Cho & Lyons, 2022).
One small uncontrolled trial of 14 people with relapsing-remitting MS found that anti-inflammatory signaling rose after 24 sessions of 808 nm treatment (Silva et al., 2020).
For a wider discussion of this pathway, see CuraYou's guide to red light therapy for inflammation.
Supporting Cellular Energy Production
Evidence tier: established mechanism in neurons; direct human-brain measurement outside MS; MS-relevant reviews
Damaged myelin makes nerve signaling less efficient. Nerve fibers need more energy to carry a signal at the same time that inflammation and oxidative stress are impairing the structures that produce that energy. Vulnerable nerve cells end up with high demand and reduced supply.
A foundational neuron study established that 670 nm and 830 nm light restored energy production after metabolic toxins had shut it down. The wavelengths that worked best matched the light-absorption pattern of the specific enzyme involved, which is what established cellular energy production as the central mechanism of photobiomodulation (Wong-Riley et al., 2005).
Red light's effect on brain energy has since been measured in living people. In a small study of healthy older adults, brain imaging showed a significant increase in the rate of energy production after 670 nm treatment applied to the head. The study did not involve MS; it is still the first direct evidence that light changes brain energy output in humans (Fear et al., 2023).
Two 2026 reviews place cellular energy at the center of why photobiomodulation research is relevant to MS, identifying energy and inflammatory pathways as the most consistently observed effects of near-infrared light in white-matter disease (Zhang et al., 2026; De Ridder, Hamblin & Vanneste, 2026). Both reviews strengthen the mechanistic case without replacing the human MS trials the field still needs.
Lowering Oxidative and Nitrosative Stress
Evidence tier: causal animal experiment; human-cell study; one null human result
Oxidative and nitrosative stress occur when reactive molecules build up faster than the body can neutralize them. In MS, that burden damages energy-producing structures, the cells that make myelin, and the nerve fibers themselves.
The strongest mechanistic finding in the entire MS photobiomodulation literature is a causal one. Researchers tested 670 nm light in mice bred without the ability to produce an enzyme that generates damaging nitrogen compounds. In those mice, the treatment stopped working entirely. That result establishes that this pathway is required for the benefit seen in the animal model. The same study found the treatment shifted cell-survival signaling away from programmed cell death (Muili et al., 2013).
Human cell evidence runs the same direction: at 830 nm, treatment reduced a key marker of nitrogen-compound damage in immune cells from people with MS, and the reduction tracked with shifts toward anti-inflammatory signaling (Tolentino, Cho & Lyons, 2022).
The pathway is well-supported in cells and in animal models; demonstrating it in a person with MS is the step that has not been taken.
Protecting Myelin and Supporting Repair
Evidence tier: animal findings across two disease models; no human remyelination trial
Myelin loss is the defining feature of MS. In animal work, photobiomodulation has been associated with less myelin damage and better movement outcomes.
In one MS-model study, both 660 nm and 904 nm treatment lowered disease scores, delayed symptom onset, reduced inflammatory-cell entry into the central nervous system, and protected against myelin loss (Gonçalves et al., 2016). A separate mouse model that causes myelin damage without an autoimmune trigger (isolating the repair question) found that treatment through the skull reduced damage, increased reserve cells capable of producing new myelin, and improved motor coordination (Duarte et al., 2018).
A 2026 review of white-matter disease placed these findings in a wider framework: across models of myelin loss, appropriately dosed near-infrared treatment was associated with lower inflammatory activity and better structural outcomes (Zhang et al., 2026). Whether photobiomodulation can regrow myelin in people with MS has not been tested, and the most detailed recent animal study states that this question remains open (Escarrat et al., 2024).
Improving Muscle Function and Daily Performance
Evidence tier: one small double-blind crossover trial; additional randomized and nonrandomized human studies
The human evidence for red light therapy in MS is strongest in muscle performance, because muscle performance is where researchers measured something objective rather than relying on how participants felt.
Seventeen people with MS completed a randomized, double-blind crossover trial in which each person received both active treatment and placebo, serving as their own control. A single high-dose session improved force recovery after fatiguing exercise, reaching 101.89% of baseline after active treatment versus 96.3% after placebo (p = 0.03). Two weeks of individualized treatment increased mean muscle force from 162.70 N to 185.56 N (p = 0.01), a significant gain over the placebo period (p = 0.02). Those are dynamometer readings, not questionnaire scores. The Rouhani crossover trial found no significant improvement in muscle fatigue or endurance time with either treatment condition (Rouhani et al., 2024).
A larger 2016 study randomized 120 people with MS across four rehabilitation programs. Functional status improved across the programs, with the strongest results when laser therapy was combined with magnetostimulation. Because the programs included other rehabilitation components and no sham-light comparison, the study supports clinical potential without cleanly isolating what the light contributed (Kubsik et al., 2016).
A 2022 nonrandomized study enrolled 40 participants, with 32 completing treatment. The group receiving pulsed laser therapy showed significant short-term improvements in fatigue, cognitive performance, and disability scores after 12 sessions. (Essa & Shendy, 2022).
Fatigue is where the evidence splits. The Essa and Shendy study reported improvement. The Rouhani crossover trial measured fatigue directly and found none. A separate pilot study also found no significant change on a standard fatigue scale (Silva et al., 2022). Different sites, doses, and schedules may explain part of the disagreement, but the existing evidence cannot determine which protocol matters or whether light helps MS fatigue at all.
Conclusion
Red light therapy for multiple sclerosis has moved past a purely theoretical idea. A placebo-controlled trial measured real gains in muscle strength and force recovery. Animal and human-cell research offers a connected explanation involving inflammation, cellular energy, oxidative stress, and myelin protection. One mechanism (the nitrosative stress pathway) has been established as causally necessary in the animal model, which is a higher bar than most complementary therapies clear.
MS patients ask what they can do beyond their medication, and the honest answer has always been exercise, rehab, and managing symptoms as they come. What makes this research worth watching is that it's asking whether light can reach the cellular problems that keep accumulating even when the immune attack is controlled: the energy failure, the inflammation that won't resolve. The data is early. But the question is the right one.— Dr. William Carter, MD
